Comparison
21q22 11q22 12 Microdeletion Syndrome C5192593 vs 14q32 Duplication Syndrome C4225449
Clinical comparison between 21q22 11q22 12 Microdeletion Syndrome and 14q32 Duplication Syndrome for differential diagnosis and treatment planning.
21q22 11q22 12 Microdeletion Syndrome C5192593
A rare genetic condition involving deletion of a specific region on chromosome 21. It may cause developmental delay, intellectual disability, and distinctive facial features. Management focuses on developmental support and medical monitoring.
14q32 Duplication Syndrome C4225449
A rare chromosomal disorder where extra genetic material from chromosome 14 is present. It can affect development and cause intellectual disability, distinctive facial features, and other health issues. Management focuses on addressing symptoms with specialized care.
6 comparison axes
Onset
21q22 11q22 12 Microdeletion Syndrome C5192593
0-0
14q32 Duplication Syndrome C4225449
0-0
Onset patterns differ
Severity
21q22 11q22 12 Microdeletion Syndrome C5192593
severe
14q32 Duplication Syndrome C4225449
moderate
Different severity levels
Chronic
21q22 11q22 12 Microdeletion Syndrome C5192593
Chronic
14q32 Duplication Syndrome C4225449
Chronic
Differing course
Communicable
21q22 11q22 12 Microdeletion Syndrome C5192593
No
14q32 Duplication Syndrome C4225449
No
Different transmission
Body System
21q22 11q22 12 Microdeletion Syndrome C5192593
congenital
14q32 Duplication Syndrome C4225449
congenital
Same/different system
Category
21q22 11q22 12 Microdeletion Syndrome C5192593
rare-disease
14q32 Duplication Syndrome C4225449
genetic
Different category
Bottom line
21q22-11q22-12-microdeletion-syndrome-C5192593 and 14q32-duplication-syndrome-C4225449 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 21q22 11q22 12 Microdeletion Syndrome C5192593 | 14q32 Duplication Syndrome C4225449 | Discriminating power |
|---|---|---|---|
| Chromosomal change | Described as deletion of a specified chromosome 21 region. | Described as extra genetic material from chromosome 14, including 14q32. | High |
| Development and cognition | May include developmental delay and intellectual disability; severity varies and is not fully defined here. | May affect development and cause intellectual disability; individual range is not established. | Low |
| Facial appearance | Distinctive facial features are reported, but specific features are not supplied. | Distinctive facial features may occur, without a defined feature list here. | Low |
When to favor each condition
Choose 21q22 11q22 12 Microdeletion Syndrome C5192593 when
A validated test shows deletion of the named chromosome 21 interval.
The defining evidence is loss of that chromosomal material.
High
The laboratory report specifically names this microdeletion syndrome.
The report label matches the left condition rather than a duplication.
High
Counseling concerns a deletion-related congenital condition.
Management still centers on individualized developmental support and monitoring.
Moderate
Choose 14q32 Duplication Syndrome C4225449 when
Testing confirms extra material involving 14q32.
The defining evidence is duplication rather than deletion.
High
The report specifically identifies 14q32 duplication syndrome.
The chromosomal location and copy-number gain match the right condition.
High
Care planning addresses symptoms associated with this duplication.
Support is symptom-focused because the full phenotype is not established here.
Moderate
How key tests differ
| Test | 21q22 11q22 12 Microdeletion Syndrome C5192593 | 14q32 Duplication Syndrome C4225449 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May detect a copy-number loss in the relevant chromosome 21 region. | May detect a copy-number gain involving 14q32. | Copy-number direction and location are the main distinction; laboratory confirmation is required. |
| Karyotype | A small deletion may not be visible. | A small duplication may also be missed. | A normal karyotype does not exclude either condition. |
| Targeted confirmation test | May verify the reported chromosome 21 deletion when clinically indicated. | May verify the reported 14q32 duplication when clinically indicated. | Method selection depends on the laboratory and clinician; no single cutoff is established here. |
Prognosis comparison
21q22 11q22 12 Microdeletion Syndrome C5192593
- Outcome
- A chronic congenital course is described, with potentially substantial developmental impact; precise outcomes are not established.
- Factors
- Confirmed deletion, individual developmental profile, and associated medical needs.
14q32 Duplication Syndrome C4225449
- Outcome
- A chronic course with variable developmental effects is described; precise outcomes are not established.
- Factors
- Confirmed duplication, symptom pattern, and access to specialized support.
Time frame: Often recognized in early life, but onset details are not established by the supplied values.
Source severity labels differ, but individual prognosis cannot be inferred reliably.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental needs | Support needs may be substantial, but exact deficits are not established. Developmental effects may occur across a variable range. Neither description provides a definitive complication profile. |
| Associated medical issues | Monitoring is advised, but specific organ complications are not listed. Other health issues are mentioned without specification. Do not infer particular complications from these sparse data. |
| Family implications | Genetic counseling may be appropriate after confirmed deletion. Counseling may also be appropriate after confirmed duplication. Inheritance and recurrence cannot be determined from the supplied information. |
Patient education highlights
- HighDiagnosis
An abnormal chromosomal finding requires specialist confirmation and is not by itself a complete clinical picture.
- HighCare
Both conditions are managed through individualized developmental, educational, and medical support rather than a single established treatment.
- MediumUncertainty
Available descriptions do not establish exact symptoms, prognosis, prevalence, or complication rates.